Printer Friendly

STERLING WINTHROP AND SANOFI ANNOUNCE INITIATION OF ALLIANCE OPERATIONS IN GERMANY

         STERLING WINTHROP AND SANOFI ANNOUNCE INITIATION
                OF ALLIANCE OPERATIONS IN GERMANY
    NEW YORK, Nov. 15 /PRNewswire/ -- Sterling Winthrop Inc. and Sanofi today announced the initiation of pharmaceutical and consumer health products alliance operations in Germany.  Final agreements creating the alliance organizations were signed on Oct. 31, 1991.  In August, the companies announced initiation of alliance pharmaceutical operations in the United States and France, and consumer health products alliance operations in France.
    "The progress of building our global alliance continues smoothly," said Louis P. Mattis, chairman, president and chief executive officer of Sterling Winthrop.  "We expect to announce initiation of operations in other countries around the end of the year."
    The pharmaceutical alliance organization will operate as Sanofi Winthrop and will be managed by Sanofi.  Key products will include Muskel Trancopal (chlormezanone) muscle relaxant, Winobanin (danazol) hormonal agent, Fortral (pentazocine) analgesic, Musaril (tetrazepam) muscle relaxant, Fraxipairn (low molecular weight heparin) antithrombotic, Calciparin (calcium heparin) antithrombotic, Cordarex (amiodarone) antiarrhythmic, and Tiklyd (ticlopidine) platelet antiaggregant.
    The consumer health products alliance organization, to be managed by Sterling Winthrop, will market products under the name Sterling Health.
    Sterling Winthrop and Sanofi Alliance
    As a result of the alliance, Sterling Winthrop and Sanofi will rank among the top 20 pharmaceutical companies, with annual sales of more than $2 billion.  The alliance will be among the leaders in pharmaceutical R&D, with combined expenditures of approximately $500 million, supported by more than 3200 scientific and support personnel. Consumer health products operations will rank as a leader in Europe.
    The Sterling Winthrop and Sanofi alliance benefits from the geographic complementarity of the two companies, their similar research orientation and their common vision.  The alliance is well positioned to meet the challenges in the next decade, and to rapidly introduce innovative and improved products.
    Alliance Vision
    Together, Sterling Winthrop Inc., headquartered in New York City, and Sanofi, headquartered in Paris, have developed a common vision for the alliance which states: "Together, we are a worldwide team committed to creating distinctive solutions for the needs of mankind in pharmaceutical and consumer health products."
    -0-         11/15/91
    /CONTACT:  Terry G. Kelley, 212-907-3009, or David M. Marcou, 212-907-2672, both of Sterling Winthrop/ CO:  Sterling Winthrop Inc.; Sanofi ST:  New York IN:  MTC SU: SM-OS -- NY079 -- 1684 11/15/91 15:56 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 15, 1991
Words:381
Previous Article:CAYUGA SAVINGS AND HOMESTEAD UNITE
Next Article:'EVEN EAGLES NEED A PUSH' NEW BOOK RELEASED BY DELACORTE PRESS
Topics:


Related Articles
SANOFI WINTHROP AND RHONE-POULENC RORER INC. SIGN MARKETING, DISTRIBUTION AGREEMENT FOR ANTI-ANGINAL
NEORX CORPORATION AND STERLING WINTHROP INC. SIGN LICENSE AGREEMENT FOR CANCER RADIOIMMUNOTHERAPY TECHNOLOGY
CONTRAST MEDIA RESEARCH ALLIANCE FORMED BY STERLING WINTHROP AND STANFORD UNIVERSITY
BRISTOL-MYERS SQUIBB, STERLING WINTHROP INC. AND ELF SANOFI ANNOUNCE CARDIOVASCULAR DEVELOPMENT EFFORT
STERLING WINTHROP AND ELF SANOFI ANNOUNCE JOINT DEVELOPMENT AND COMMERCIALIZATION OF TWO NEW AGENTS WITH BRISTOL-MYERS SQUIBB
BRISTOL-MYERS SQUIBB, STERLING WINTHROP INC. AND ELF SANOFI ANNOUNCE CARDIOVASCULAR DEVELOPMENT EFFORT
STERLING WINTHROP AND ELF SANOFI ANNOUNCE FINAL AGREEMENT FOR JOINT DEVELOPMENT, COMMERCIALIZATION OF TWO AGENTS WITH BRISTOL-MYERS SQUIBB
BRISTOL-MYERS SQUIBB, STERLING WINTHROP AND ELF SANOFI FINALIZE CARDIOVASCULAR DEVELOPMENT AGREEMENT
STERLING WINTHROP INC. EXPANDS CONSUMER HEALTH ALLIANCE OPERATIONS IN RUSSIA AND CENTRAL AND EASTERN EUROPE
Gensia Sicor Appoints Sanofi Winthrop Exclusive Distributor for Brevibloc In U.K. and Ireland

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters